# Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-first-line-maintenance-therapy-with-lurbinectedin-plus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Luis Paz‐Ares,Hossein Borghaei,Stephen V. Liu,Solange Peters,Roy S. Herbst,Katarzyna Stencel,Margarita Majem,Mehmet Alı Nahıt Şendur,Grzegorz Czyżewicz,Reyes Bernabé Caro,Ki Hyeong Lee,Melissa L. Johnson,Nuri Karadurmuş,Christian Grohé,Sofia Baka,Tibor Csőszi,Jin Seok Ahn,Raffaele Califano,Tsung‐Ying Yang,Yasemi̇n Kemal,Marcus Ballinger,Vaikunth Cuchelkar,Vilma Graupner,Ya‐Chen Lin,Debasis Chakrabarti,Kamalnayan Bhatt,George Cai,Robert Iannone,Martin Reck |
| Citations | 78 |
| DOI | 10.1016/s0140-6736(25)01011-6 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4410947809 |
| PMID | 40473449 |
| Type | article |
| Year | 2025 |

## Paper authors

- [Tsung‐Ying Yang](https://scholariq.org/researchers/tsung-ying-yang/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.